AVITA Medical, Inc.

NasdaqCM:RCEL Stock Report

Market Cap: US$338.9m

AVITA Medical Management

Management criteria checks 2/4

AVITA Medical's CEO is Jim Corbett, appointed in Sep 2022, has a tenure of 2.25 years. total yearly compensation is $2.07M, comprised of 30.2% salary and 69.8% bonuses, including company stock and options. directly owns 0.033% of the company’s shares, worth $112.17K. The average tenure of the management team and the board of directors is 1.8 years and 6.2 years respectively.

Key information

Jim Corbett

Chief executive officer

US$2.1m

Total compensation

CEO salary percentage30.2%
CEO tenure2.3yrs
CEO ownership0.03%
Management average tenure1.8yrs
Board average tenure6.2yrs

Recent management updates

Recent updates

AVITA Medical, Inc.'s (NASDAQ:RCEL) Shares Bounce 26% But Its Business Still Trails The Industry

Dec 03
AVITA Medical, Inc.'s (NASDAQ:RCEL) Shares Bounce 26% But Its Business Still Trails The Industry

AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Oct 04
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 11
AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jul 18
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Jun 18
Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding

Apr 12
Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding

AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%

Feb 02
AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%

The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%

Oct 20
The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%

Avita Medical appoints James Corbett as CEO

Sep 29

AVITA Medical says trial evaluating its RECELL system to treat vitiligo met main goal

Sep 12

Avita's burn therapy Recell gets insurance coverage in Japan following approval

Sep 01

AVITA Medical GAAP EPS of -$0.25 beats by $0.15, revenue of $8.34M beats by $1.18M

Aug 11

AVITA Medical Is Interesting, But Not Just Yet

Dec 21

AVITA Medical reports preliminary Q2 revenue in-line with consensus

Jan 12

CEO Compensation Analysis

How has Jim Corbett's remuneration changed compared to AVITA Medical's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$57m

Jun 30 2024n/an/a

-US$50m

Mar 31 2024n/an/a

-US$45m

Dec 31 2023US$2mUS$625k

-US$35m

Sep 30 2023n/an/a

-US$34m

Jun 30 2023n/an/a

-US$31m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$2mUS$157k

-US$27m

Sep 30 2022n/an/a

-US$30m

Jun 30 2022n/an/a

-US$30m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$256kn/a

-US$25m

Compensation vs Market: Jim's total compensation ($USD2.07M) is about average for companies of similar size in the US market ($USD2.15M).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.

CEO

Jim Corbett (66 yo)

2.3yrs

Tenure

US$2,068,675

Compensation

Mr. James M. Corbett, also known as Jim, served as Chief Executive Officer of CathWorks Ltd. since October 27, 2017 until 2021. He serves as Director of CathWorks Ltd.until 2021. He served as an Independe...

Leadership Team

NamePositionTenureCompensationOwnership
James Corbett
CEO, President & Executive Director2.3yrsUS$2.07m0.033%
$ 112.2k
David O'Toole
Chief Financial Officer1.5yrsUS$2.18mno data
David Fencil
Senior Vice President of Global Operations1.8yrsno datano data
Katie Bush
Senior Vice President of Scientific & Medical Affairsless than a yearno datano data
Jessica Ekeberg
Investor Relations Executiveno datano datano data
Nicole Kelsey
Chief Legal & Compliance Officer and Corporate Secretaryless than a yearno datano data
Debbie Garner
Senior Vice President of Global Marketing & Strategy6.4yrsno datano data
Rob Hall
Senior Vice President of Human Resources1.8yrsno datano data
Niraj Doshi
Senior Vice President of Product Development & Program Management1.8yrsno datano data
Ron Lagerquist
Senior Vice President of Quality Assurance & Regulatory Affairs1.8yrsno datano data
Robin VanDenburgh
Senior Vice President of U.S. Commercial Salesless than a yearno datano data

1.8yrs

Average Tenure

Experienced Management: RCEL's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
James Corbett
CEO, President & Executive Director3.4yrsUS$2.07m0.033%
$ 112.2k
Jan Reed
Independent Non-Executive Director3.4yrsUS$211.12k0.11%
$ 373.1k
Jeremy Curnock-Cook
Independent Non-Executive Director12.2yrsUS$199.87k0.079%
$ 266.1k
Fiona Wood
Founder and Member of Clinical Advisory Board8.9yrsUS$29.80kno data
Louis Panaccio
Independent Non-Executive Chairman10.4yrsUS$234.69k0.16%
$ 557.4k
Robert McNamara
Independent Non-Executive Director1.7yrsUS$369.11k0.075%
$ 253.5k
Cary Vance
Independent Non-Executive Director1.7yrsUS$364.94k0.037%
$ 124.4k
Suzanne Crowe
Independent Non-Executive Director8.9yrsUS$195.28k0.10%
$ 351.5k

6.2yrs

Average Tenure

67yo

Average Age

Experienced Board: RCEL's board of directors are considered experienced (6.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 10:45
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AVITA Medical, Inc. is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Lyanne HarrisonBofA Global Research
Laura McGuiganB. Riley Securities, Inc.